Evidence mapPaperPMID 41617993Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

A network pharmacology-based study on the mechanism of hirudin attenuates renal interstitial fibrosis through Nrf2 and NF-κB signalling pathways.

Kang Yang, Yijiao Wang, Xiaoxia Xun, Hao Zhao, Guanting Chen, Tao Li, Jinhua Ge, Siyu Guo, Shengtao Ye, Zhenzhen Wang and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kang YangTreatment Center of Kidney Disease, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450003, China.
Yijiao WangAcademy of Chinese Medical Science, Henan University of Chinese Medicine, Zhengzhou, 450046, China.
Xiaoxia XunTreatment Center of Kidney Disease, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450003, China.
Hao ZhaoAcademy of Chinese Medical Science, Henan University of Chinese Medicine, Zhengzhou, 450046, China.
Guanting ChenTreatment Center of Kidney Disease, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450003, China.
Tao LiTreatment Center of Kidney Disease, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450003, China.
Jinhua GeTreatment Center of Kidney Disease, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450003, China.
Siyu GuoAcademy of Chinese Medical Science, Henan University of Chinese Medicine, Zhengzhou, 450046, China.
Shengtao YeAcademy of Chinese Medical Science, Henan University of Chinese Medicine, Zhengzhou, 450046, China.
Zhenzhen WangAcademy of Chinese Medical Science, Henan University of Chinese Medicine, Zhengzhou, 450046, China. wzlinxi@163.com.
Yaoxian WangAcademy of Chinese Medical Science, Henan University of Chinese Medicine, Zhengzhou, 450046, China. wyx3203@sina.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study was aimed at elucidating the therapeutic effects of hirudin on renal interstitial fibrosis (RIF) and at delineating the molecular mechanisms underlying its antifibrotic actions. A comprehensive research approach was adopted, integrating network pharmacology, molecular docking, molecular dynamics simulations, and in vitro experimental validation, to explore the mechanisms through which hirudin alleviates RIF. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis identified 185 enriched signalling pathways, with the primary ones being the VEGF signalling pathway, TNFA signalling pathway and NF-κB signalling pathway. Gene Ontology (GO) analysis revealed that hirudin's antifibrotic effects were associated with inflammatory responses, canonical NF-κB signal transduction, and cellular responses to oxidative stress. Protein-protein interaction (PPI) network analysis identified TNF, HIF1A, HO-1, CASP3, IKBA, KEAP1, and RELA as key hub proteins. Experimental validation demonstrated that hirudin significantly reduced the protein levels of fibronectin (FN) and collagen I (Col I) in TGF-β1-stimulated HK-2 cells. Additionally, hirudin downregulated pro-inflammatory markers (TNF-α, MCP-1, p-P65, and p-IκBα) while upregulating antioxidant proteins (Nrf2, HO-1, and SOD-1). These findings suggest that hirudin mitigates TGF-β1-induced inflammation and oxidative stress in HK-2 cells by modulating the Nrf2 and NF-κB signalling pathways, thereby impeding the progression of RIF.

Indexed as

Antifibrotic AgentsHirudinsKidneyKidney DiseasesNF-E2-Related Factor 2NF-kappa BCell LineFibrosisHumansMolecular Docking SimulationMolecular Dynamics SimulationNetwork PharmacologyOxidative StressProtein Interaction MapsSignal TransductionAntifibrotic AgentsHirudinsNFE2L2 protein, humanNF-E2-Related Factor 2NF-kappa BCellular response to oxidative stressHirudinNetwork pharmacologyNF-κB signalling pathwayRenal interstitial fibrosis

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.